Xcout Intel
Tempest Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Tempest Therapeutics, Inc. among biotech companies — ranked by similarity to what Tempest Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Tempest Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Tempest Therapeutics, Inc.
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
Tempest Therapeutics, Inc. at a glance
Tempest Therapeutics, Inc. is a biotech company headquartered in Brisbane, United States. It is publicly listed (TPST) with a market capitalisation of $18.1M. Xcout tracks 22 named people at Tempest Therapeutics, Inc., including Matthew Angel (Chief Executive Officer, President & Director).
Tempest Therapeutics, Inc. leadership
- Matthew AngelChief Executive Officer, President & Director
- Nicholas J. RossettosCFO, Principal Financial & Accounting Officer, Treasurer and Corporate Secretary
- Justin TrojanowskiVP of Finance, Corp. Controller, Treasurer, Secretary and Principal Financial & Accounting Officer
- Andrew FangHead of Business Development
- Matthew AngelExecutive Officer
- Nicholas MaestasExecutive Officer
16 more named people on record for Tempest Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Top 12 Tempest Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Tempest Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
RAPT Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is driven by its mission to develop oral small molecule therapies to treat inflammatory and immunologic diseases.
Biotechnology
Turning Point Therapeutics is a clinical-stage precision oncology company based in San Diego, California, that designs and develops targeted cancer therapies. Founded in 2013, the company operates as a subsidiary of Bristol Myers Squibb following its acquisition in 2022.
Similar biotech company
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Similar biotech company
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Biotechnology
Tempero Bio, Inc. is a clinical-stage biopharmaceutical holding company established in 2020 and headquartered in Oakland, California. The company focuses on developing transformative therapeutics and advancing its drug pipeline through clinical trials.
Biotechnology
Revolution Medicines is a clinical-stage oncology company that develops novel targeted therapies to outsmart cancer. The company focuses on discovering and advancing therapeutic pipelines for patients with difficult-to-treat tumors.
Biotechnology
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Biotechnology
Rodeo Therapeutics Corp. is a U.S. biotechnology company developing small-molecule inhibitors of 15-prostaglandin dehydrogenase (15-PGDH) to stimulate endogenous tissue regeneration. Its programs are intended for patients with conditions involving tissue damage, including potential applications in bone marrow and intestinal repair.
Similar biotech company
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.
Similar biotech company
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Biotechnology
Aragon Pharmaceuticals, Inc. is a United States-based pharmaceutical discovery and development company founded in 2009 and headquartered in San Diego, California. The company focuses on developing small-molecule, anti-endocrine therapies and breakthrough medicines for the treatment of hormonally-driven and hormone-resistant cancers. Aragon Pharmaceuticals operates as a subsidiary of Johnson & Johnson, which completed the acquisition to strengthen its oncology pipeline.
Similar biotech company
Aptose Biosciences Inc. is a clinical-stage biotechnology company that develops small molecule cancer therapeutics, focusing on precision medicines for hematologic malignancies. The company's product pipeline features investigational drug candidates such as tuspetinib and luxeptinib, which are designed to treat conditions like acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and B-cell malignancies.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Tempest Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Tempest Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →